Rituximab is a medication that works by targeting specific immune cells called B-cells. It helps reduce inflammation in the body and is used to treat multiple sclerosis. It is given through an intravenous infusion (through a vein) in a medical setting.

Ocrelizumab is also a medication that targets B-cells in the immune system. Like rituximab, it helps manage multiple sclerosis symptoms by reducing inflammation in the nervous system. It is administered as an intravenous infusion in a healthcare facility.

Both medications work in similar ways to help treat relapsing-remitting multiple sclerosis by modifying how the immune system functions. They are considered disease-modifying therapies that can help reduce the frequency of MS relapses and slow down the progression of the disease.

Multiple Sclerosis – A chronic disease affecting the central nervous system (brain and spinal cord) where the immune system mistakenly attacks the protective covering of nerve fibers called myelin. The damage to myelin leads to communication problems between the brain and the rest of the body, causing various symptoms that can come and go. In the relapsing-remitting form, people experience distinct attacks of symptoms followed by periods of partial or complete recovery. The disease typically causes issues with vision, balance, muscle control, and other basic body functions. Over time, the disease may progress differently in each person, with some experiencing mild symptoms while others may have more significant changes in their daily activities.